A real-world study published in Clinical Infectious Diseases found that two doses of the adjuvanted recombinant shingles vaccine was estimated to be 74% effective at preventing herpes zoster (HZ) and 84% effective at preventing postherpetic neuralgia (PHN) in U.S. adults aged 50 years and older. The study, conducted by researchers from Kaiser Permanente Southern California (KPSC) in collaboration with the vaccine’s manufacturer GSK, evaluated the long-term effectiveness of the recombinant zoster vaccine. Researchers followed participants …
Read More
